Clinical Trials Logo

Clinical Trial Summary

This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety evaluations (both clinical and laboratory) are performed at baseline, before each study treatment, and throughout the study.


Clinical Trial Description

The primary objective of this phase 2 study is to assess objective response rate of SHR-1210 combined with Apatinib in patients with relapsed or refractory NK/T cell lymphoma. The secondary objective is to observe time to response,progression free survival rate at 2 years,overall survival rate at 2 years,safety and immunogenicity of SHR-1210 combined with Apatinib in relapsed or refractory NK/T cell lymphoma. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03701022
Study type Interventional
Source Peking University
Contact Yuqin Song
Phone +13683398726
Email songyuqin622@163.com
Status Not yet recruiting
Phase Phase 2
Start date October 20, 2018
Completion date June 30, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04490590 - A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma Phase 4
Recruiting NCT05662540 - PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma N/A
Recruiting NCT05833893 - Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma Phase 2
Recruiting NCT06362148 - Circulating Tumor DNA in Peripheral T-cell Lymphomas
Completed NCT03012620 - Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types Phase 2
Recruiting NCT04008394 - Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies Phase 1
Active, not recruiting NCT04425070 - A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma Phase 1/Phase 2